331 results about "Heart tissues" patented technology

The invention relates to the technical field of medical image processing, in particular to an engineered heart tissue pulsation trajectory automatic analysis method based on an image recognition algorithm, which comprises the following steps: S1, multi-modal image fusion: performing space-time registration and feature fusion on acquired multi-modal heart images to generate a fused image sequence; s2, cardiac muscle tissue segmentation: outputting a cardiac muscle tissue segmentation result with a timestamp; s3, motion track modeling: generating three-dimensional track point cloud data in a pulsation period; s4, feature parameter extraction: performing spatial-temporal feature analysis on the track point cloud data, and extracting multi-dimensional motion parameters; and S5, heterogeneity atlas generation: generating a cardiac pulse heterogeneity atlas according to the multi-dimensional motion parameters. According to the method, automatic analysis of the cardiac pulse track and generation of the heterogeneity atlas based on the multi-modal image and space-time modeling are realized, and the precision and the intelligent level of cardiac motion anomaly recognition are remarkably improved.

Embodiments of the invention include additional methods and compositions for fabricating organoids. A unique approach has been developed for the rapid aggregation of defined number of cells using a micropillar-based template to limit the size of organoids, which are then more commonly referred to as spheroids. This procedure can be utilized to create in vitro cardiac tissue models (e.g., cardiac organoids) simply, rapidly, and inexpensively. In certain aspects an alginate-gelatin based hydrogel premixed with cardiomyocytes is used in combination with a patterned microfluidic chip / cell culture chamber having an array of micropillars to fabricate 3D cardiac organoids.

System and methods are described for developing a delivery plan for a pulsed field ablation device for treating an arrhythmia. A method runs a lesion development simulation based on cardiac characteristics and a treatment plan that specifies a delivery plan and a target location to generate a simulated lesion having lesion characteristics. The method initializes a three-dimensional (3D) mesh representing a heart based on cardiac characteristics. The vertices of the 3D mesh are associated with cardiac tissue characteristics with some of the associated with cardiac tissue characteristics representing an arrhythmia source. The method adjusts the cardiac tissue characteristics of vertices of the 3D mesh to reflect the effect of an ablation resulting in formation of the simulated lesion. The method runs a lesion evaluation simulation based on the 3D mesh with the adjusted cardiac tissue characteristics to determine whether the simulated lesion would be effective at treating the arrhythmia.

Coaptation assist device for repairing cardiac valves and associated systems and methods are disclosed herein. A coaptation assist device configured in accordance with embodiments of the present technology can include, for example, a fixation member configured to press against cardiac tissue proximate to a native valve annulus, and a stationary coaptation structure extending away from the fixation member. The coaptation structure can include an anterior surface configured to coapt with a first native leaflet during systole and a posterior surface configured to displace at least a portion of a second native leaflet. The device also includes at least one sensor configured to detect parameters associated with at least one of cardiac function and device functionality. The sensors can be pressure sensors configured to detect left atrial pressure and / or left ventricular pressure.

A catheter includes: (a) a shaft for insertion into a heart of a patient, (b) an expandable distal-end assembly, which is coupled to the shaft and is configured to make contact with tissue of the heart, (c) at least first and second electrocardiogram (ECG) electrodes, which are coupled to an outer surface of the expandable distal-end assembly, and when placed in contact with the tissue, are configured to sense ECG signals in the tissue, and (d) a reference electrode, which is positioned within an inner volume of the distal-end assembly, and in an expanded position of the distal-end assembly, the reference electrode: (i) has no physical contact with the tissue, and (ii) is positioned at a first distance from the first ECG electrode and at a second distance from the second ECG electrode, and the difference between the first and second distances is smaller than a predefined threshold.

The invention belongs to the technical field of biological medicines, and particularly relates to application of oxibenzophenone in preparation of a medicine for treating pathological cardiac hypertrophy and / or heart failure. Research results in myocardial cells of primary newborn rats show that Exibenzophenone can inhibit pathological hypertrophy of myocardial cells induced by phenylephrine (PE). Animal experiments show that the epoxybenzophenone can improve cardiac dysfunction induced by aortic arch constriction (TAC) and reduce cardiac hypertrophy and cardiac tissue fibrosis. The invention provides a new drug research and development approach and a drug action target for treating pathological cardiac hypertrophy and heart failure, and has very important medicinal value.

The invention relates to a CACNA1A-based mental patient heart death intelligent identification system and method, the system comprises an immunohistochemical staining device, an image acquisition unit, an image analysis unit and an intelligent identification unit, the immunohistochemical staining device is used for performing CACNA1A immunohistochemical staining on formalin-fixed paraffin-embedded heart tissue slices; the image acquisition unit is used for shooting and obtaining a heart tissue CACNA1A immunohistochemical staining image; the image analysis unit is used for processing the heart tissue CACNA1A immunohistochemical staining image so as to determine a tissue staining region and image features thereof; and the intelligent identification unit outputs an identification prediction result of heart death of the mental patient according to the image features of the tissue staining region. Compared with the prior art, the mental patient heart death identification system can intelligently and accurately identify mental patient heart death.

Systems and methods to process motion signals obtained from at least one motion sensor during delivery of plurality of PFA pulses or pacing signals to heart tissue location(s) and determine degrees of diaphragm spasm affected by the PFA or pacing signals. In some embodiments the system identifies reduction of diaphragm spasm during delivery of PFA pulses to a certain location and upon such identification indicates that continued delivery of further PFA pulses to that certain location may cause irreversible damage to the Phrenic nerve. Additionally, or alternatively, the system utilizes the diaphragm spasm degrees measured following pacing or ablation of at least two heart tissue locations, to map the degrees of spasm affected by the ablation of various heart tissue locations and thereby enables to conduct ablation at location associated with reduced spasm.

Embodiments of methods and systems for determining electrocardiogram (ECG) depth of electrical activity. Electrical activity from a plurality of electrodes of a catheter is received; and within the electrical activity, an electrical signal originating from a depth within cardiac tissue is identified. In some embodiments, spatial electrode signal analysis of the electrical activity may be performed for each electrode of the plurality of electrodes. In some embodiments, a linear and / or non-linear combination of signal components within the electrical activity may be calculated. In some embodiments, a neural network may be provided with the electrical signals and may determine an estimated distance to the nearest activation for at least one of the plurality of electrodes. A visualization of the identified electrical signals at a specified depth within the cardiac tissue may be provided for display.

This disclosure relates to electro-anatomical mappings of cardiac tissue at different depths using a multi-electrode catheter. A multi-electrode catheter within a heart of a patient has a first plurality of electrodes on a first side and a second plurality of electrodes on a second side, wherein the first side is proximate to cardiac tissue at a first location and the second side is facing away from the cardiac tissue. Electrical activity is received from at least one electrode on the first side and the at least one electrode on the second side, and a signal analysis is performed thereon based at least in part on distances between electrodes on different sides of the multi-electrode catheter. The process is repeated for further locations of cardiac tissue in the heart, and an electro-anatomical map of the heart depicting electrical activity or scar tissue is generated based on the signal analysis.

Devices and methods for mapping tissue, such as cardiac tissue, and applying electrical energy to ablate the tissue may include an applicator region comprising two or more wire electrodes that extend between the arms of the device as well as a plurality of mapping and / or sensing electrodes (e.g., ring electrodes) on the arms and / or the elongate body. These devices may sense electrical activity using the mapping electrodes and may deliver energy between the first wire electrode and the second wire electrode to ablate, for example, cardiac tissue.

A system and method for performing virtual birefringence imaging and virtual staining (e.g., Congo red) of label-free human tissue is disclosed to show that a single trained neural network can rapidly transform autofluorescence images of label-free tissue into brightfield and polarized microscopy images, matching their histochemically-stained versions. Blind testing with quantitative metrics and pathologist evaluations on cardiac tissue showed that the virtually stained polarization and brightfield images highlight amyloid patterns in a consistent manner, mitigating challenges due to variations in chemical staining quality and manual imaging processes in the clinical workflow.

Electro-anatomical mappings of cardiac tissue are created at different depths using a multi-electrode catheter that collects electrical activity from within a heart of a patient. A signal analysis of electrical activity at a first location is performed based on electrical activity received from a plurality of electrodes. A depth of electrical activity at the first location is determined in accordance with the signal analysis. This process is repeated for a plurality of further surface locations of cardiac tissue and at more than one depth. A plurality of electro-anatomical maps of the heart are generated, wherein the maps depict electrical activity at different depths of the cardiac tissue.

A prosthetic mitral valve includes an anchor assembly, a strut frame, and a plurality of replacement leaflets secured to the annular strut frame. The anchor assembly includes a ventricular anchor, an atrial anchor, and a central portion therebetween. The ventricular anchor and the atrial anchor are configured to flare radially outwards relative to the central portion. The annular strut frame is disposed radially within the anchor assembly and is attached to the anchor assembly. The central portion is configured to align with a native valve orifice and the ventricular anchor and the atrial anchor are configured to compress native cardiac tissue therebetween.

A heart organoid of at least 60% cardiac cells irrespective of optional additional cells of a vascular system of the organoid, or including at least 50% cardiac cells; wherein the cardiac cells surround an inner cavity, wherein the cardiac cells are selected from the group of cardiomyocytes, endocardial cells and epicardial cells, and wherein the heart organoid includes cardiomyocytes or endocardial cells that directly face the inner cavity, a method for the generation of such a tissue model and uses thereof.

The application provides a sub-threshold heart communication method, system, device, medium and application, and belongs to the technical field of biomedical engineering. The method comprises the following steps: constructing a communication channel formed by coupling of multiple three-dimensional myocardial cell models; modulating physiological information into a sub-threshold electrical signal and injecting the signal into the channel for transmission; demodulating the signal at a receiving end to recover the information; wherein a physiological noise model is integrated in the channel to simulate a real physiological environment. The system corresponds to a transmitting end, a communication channel and a receiving end. The application adopts the sub-threshold heart communication method, system, device, medium and application, the three-dimensional myocardial cell model is used to more truly simulate a heart tissue structure, the complete communication process simulation of the sub-threshold electrical signal in a noise environment is realized for the first time, the existing research gap is filled, and an innovative technical platform is provided for research on cardiac electrophysiological mechanisms, performance optimization and evaluation of implantable medical devices such as a cardiac pacemaker.

The present application discloses an implant, a transcatheter constriction ring system and their applications for reducing the risk of detachment. The implant includes a tightening wire and a plurality of anchoring components. The anchoring component includes an anchor and a threading structure rotatably sleeved on the anchor. The anchor is used for anchoring into heart tissue, and the threading structure is used for connecting the tightening wire. Among them, after a plurality of anchoring components are arranged along the circumferential direction of the heart tissue, the tightening wire is connected to the threading structure, and the tightening wire is located on the same side of the plurality of anchors that are anchored into the heart tissue. In this way, it can be ensured that after the constriction ring is completed, the anchoring components in the middle part are less stressed and the stress is more uniform, avoiding the situation where the anchoring components are stressed greatly, reducing the risk of detachment of the anchoring components, and making the implant safer; at the same time, the acting force of the anchoring components on the heart tissue is reduced, reducing the risk of damage to the heart tissue. In addition, when the tightening wire is tightened to form a constriction ring, the tightening wire moves stably and smoothly, ensuring the stability of the constriction ring and good constriction effect.

The invention relates to an application of a nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases, the nano antibody is an NB21 nano antibody, and the NB21 nano antibody has an amino acid sequence as shown in SEQ ID No.12. The invention also relates to an application of the nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases. The antibody can specifically block a Wnt / beta-catenin pathway, effectively inhibit expression of proinflammatory factors and relieve inflammatory response of heart tissues, so that occurrence and development of cardiovascular diseases are intervened. The nano antibody has significant advantages in the aspects of intervention accuracy, conversion reliability and the like, and preclinical results show that the nano antibody can improve occurrence and development of ischemic cardiomyopathy; the pharmaceutical composition can be used for treating heart failure, myocarditis and adriamycin cardiomyopathy, can be expanded to systemic inflammatory diseases, realizes the trans-boundary application of one drug with multiple targets, fully verifies the anti-inflammatory effectiveness and safety through in-vivo and in-vitro experimental data, provides new targets, diagnostic tools and accurate intervention schemes for diagnosis and treatment of cardiovascular diseases and systemic inflammatory diseases, and has wide application prospects. The obvious scientific innovation significance and clinical transformation value are realized.

The invention belongs to the technical field of medical information processing, and particularly discloses a regression model establishment method and system for detecting related indexes of myocardial cells of Wuzhishan pigs by using blood biochemical indexes, and the method comprises the following steps: collecting blood and heart tissue samples of the Wuzhishan pigs at different month ages, detecting the blood biochemical indexes including liver function, blood fat and blood sugar indexes, and establishing a regression model for detecting the related indexes of myocardial cells of the Wuzhishan pigs. Related indexes of myocardial cells; analyzing the index expression quantity difference, and screening significant difference indexes; then calculating the correlation between the remarkably different blood biochemical indexes and myocardial cell related indexes, and determining high-correlation blood biochemical indexes; and finally, constructing a first version of multiple regression model by respectively taking the myocardial enzyme index and the myocardial cell related index as dependent variables and the high-correlation blood biochemical index as an independent variable, removing outliers and updating the sample set on the basis of the first version of multiple regression model, and constructing a second version of multiple regression model by utilizing the new sample set, and on the basis of the second version of multiple regression model, constructing a third version of multiple regression model by adopting a stepwise regression method. According to the method, related indexes of myocardial cells can be accurately deduced through blood biochemical indexes, and support is provided for Wuzhishan pig heart disease research and model animal research and development.

System for use with tissue of a heart comprises a tissue anchor comprising an engaging head that has a coupling eyelet that defines an eyelet plane, and a helical tissue-coupling element, reversibly anchorable to the tissue, and having a central helix axis that lies on the eyelet plane. The system also comprises an anchor driver, having a distal portion that has a casing that defines a slot, the slot defining a slot plane, and dimensioned to receive at least part of the eyelet therein in a manner in which the eyelet plane is coplanar with the slot plane. The anchor driver also comprises a detent, configured to reversibly inhibit movement of the eyelet with respect to the slot. The anchor driver is configured to anchor the tissue anchor to the tissue by rotating the tissue anchor by applying a rotational force to the eyelet. Other embodiments are also provided.

To provide a system and method for generating, visualizing, and displaying cardiac signal information present at different depths in cardiac tissue. [Solution] Electroanatomical mapping of cardiac tissue is created at different depths using a multi-electrode catheter that collects electrical activity from within the patient's heart. Signal analysis of the electrical activity at a first location is performed based on the electrical activity received from multiple electrodes. The depth of the electrical activity at the first location is determined according to the signal analysis. This process is repeated at more than one depth for multiple further surface locations of the cardiac tissue. Multiple electroanatomical maps of the heart are generated, and the maps show the electrical activity at different depths of the cardiac tissue.

Provided herein are epicardium-derived paracrine factors for repairing heart tissue. In particular, provided herein are compositions and kits comprising epicardium-derived paracrine factors, such as hypoglycosylated follicular- stimulating hormone-like 1 (FSTL1), for treating and repairing damage to heart tissue caused by cardiovascular disease, myocardial infarction (MI), other ischemic events, or heart growth defects, and methods of using the same.

Systems and methods for clustering wavefront signals in an electrophysiology map of cardiac tissue are provided. The systems and methods include receiving an electrophysiology map of the cardiac tissue, displaying propagation of the wavefront signals as a plurality of velocity vectors, discretizing the received electrophysiology map into a plurality of segments, clustering the velocity vectors into at least one group within each segment based on predefined criteria, and generating a trend line representing each group of clustered velocity vectors within each segment in the electrophysiology map.

A catheter deploys a flexible electrode that is at least partially made of preformed hydrogel to a target location in order to provide radiofrequency catheter ablation. The catheter stores the flexible electrode, which can be deployed and retracted. The preformed hydrogel is conductive and thus can provide an interface between a conductive metal wire and a target cardiac tissue. Electric energy is applied to the portions of the cardiac tissue target tissue that are the genesis of the errant and abnormal heartbeats via the flexible electrode. The electric energy may create lesions with lower risks of steam pops and tissue perforation.

The invention discloses a mouse primary cardiac endothelial cell extraction method, and belongs to the technical field of biological cell extraction. The method comprises the following steps: step 1, obtaining pure myocardial tissues; 2, the treated heart tissue is transferred into an intelligent tissue grinding system to be ground; step 3, transferring the ground heart tissue into a temperature-controlled enzymolysis reactor, automatically monitoring the digestion process, and terminating the reaction when a preset digestion degree is reached; step 4, carrying out primary cell separation, carrying out magnetic separation by using anti-CD31 magnetic beads, and specifically enriching heart endothelial cells; 5, transferring the purified endothelial cells to an intelligent microenvironment culture system, and automatically optimizing a culture medium replacement period to adapt to a cell metabolism state; and step 6, performing multi-dimensional quality evaluation on the endothelial cells, wherein the multi-dimensional quality evaluation comprises marker expression analysis, in-vitro lumen formation experiment, AI-assisted morphological analysis and digital quality scoring.

The present invention generally relates to the field of recombinant gene expression in host cells. In particular, the invention relates to a recombinant human myeloid-derived growth factor (MYDGF) protein that exhibits a minimal degree of degradation upon expression in a host cell. The recombinant protein is therefore highly suitable for medical use, in particular for treating heart tissue damage and preventing cell death in myocardial tissue. The invention also provides a nucleic acid which encodes the recombinant protein and a host cell that expresses the recombinant protein. The invention also provides a method for producing the recombinant protein in a host cell.

A method includes s inserting, into a heart of a patient, a catheter having multiple electrodes, and placing the electrodes in contact with tissue of the heart. For each of the electrodes: (i) position signals indicative of a position of the electrode, and (ii) electrocardiogram (ECG) signals acquired by the electrode, are received during a predefined time interval. A positioning stability, along the predefined time interval, is calculated for each of the electrodes based on the position signals. For the electrodes whose positioning stability has an error smaller than a given threshold, calculating whether the ECG signals are indicative of an atrial fibrillation (AF) in the heart. The ECG signals that are indicative of the AF are stored.

The present invention provides novel capsid variants comprising a first amino acid sequence comprising the amino acid sequence RGDR (SEQ ID NO: 4286) or RGDY (SEQ ID NO: 4287) and a second amino acid sequence comprising the amino acid sequence RGD. These novel capsid variants de-target liver tissue and target muscle and heart tissue.

The therapeutic catheter is part of a system that includes a local impedance indicator displayed on a screen. The local impedance indicator displays relative changes in impedance to the user to quickly convey information that helps the user better understand where the catheter is positioned within the cardiac chamber.